Eikon Therapeutics Inc. Common Stock

EIKN | NASDAQ

$5.31

-$0.04 (-0.75%)

At close: Oct 30, 2026, 4:00 PM ET

$5.49

+$0.18 (+3.39%)

Pre-market: Nov 2, 2026, 4:00 AM ET

TTM Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025
Revenue	n/a	n/a	n/a	n/a
Cost of Revenue	15.25M	10.22M	5.11M	n/a
Gross Profit	-15.25M	-10.22M	-5.11M	n/a
Operating Income	-338.65M	-245.26M	-157.92M	-74.75M
Interest Income	12.89M	7.85M	3.47M	n/a
Pretax Income	-322.16M	-233.75M	-150.79M	-71.14M
Net Income	-322.16M	-233.75M	-150.79M	-71.14M
Selling & General & Admin	58.46M	45.55M	33.38M	15.44M
Research & Development	270.05M	194.59M	124.54M	59.31M
Other Expenses	-5.11M	-5.11M	-5.11M	n/a
Operating Expenses	323.4M	235.04M	152.81M	74.75M
Interest Expense	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a
Cost & Expenses	338.65M	245.26M	157.92M	74.75M
Income Tax Expense	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	54.15M	54.14M	54.14M	n/a
Shares Outstanding (Diluted)	54.15M	54.14M	54.14M	n/a
EPS (Basic)	-4.63	-3	-1.47	n/a
EPS (Diluted)	-4.63	-3	-1.47	n/a
EBITDA	-297.15M	-208.78M	-130.94M	-56.39M
EBIT	-318.69M	-225.3M	-142.34M	-62.68M
Depreciation & Amortization	21.54M	16.52M	11.4M	6.3M